Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER2-Low Breast Cancer: Where Are We?
Molinelli C, Jacobs F, Marchiò C, Pitto F, Cosso M, Spinaci S, de Azambuja E, Schettini F, Agostinetto E, Lambertini M. Molinelli C, et al. Among authors: lambertini m. Breast Care (Basel). 2022 Dec;17(6):533-545. doi: 10.1159/000527391. Epub 2022 Oct 6. Breast Care (Basel). 2022. PMID: 36590146 Free PMC article. Review.
Twenty years of anti-HER2 therapy-associated cardiotoxicity.
Pondé NF, Lambertini M, de Azambuja E. Pondé NF, et al. Among authors: lambertini m. ESMO Open. 2016 Jul 21;1(4):e000073. doi: 10.1136/esmoopen-2016-000073. eCollection 2016. ESMO Open. 2016. PMID: 27843627 Free PMC article. Review.
Adjuvant trastuzumab: a 10-year overview of its benefit.
Lambertini M, Pondé NF, Solinas C, de Azambuja E. Lambertini M, et al. Expert Rev Anticancer Ther. 2017 Jan;17(1):61-74. doi: 10.1080/14737140.2017.1264876. Epub 2016 Dec 5. Expert Rev Anticancer Ther. 2017. PMID: 27883296 Review.
Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
Poggio F, Ceppi M, Lambertini M, Bruzzi P, Ugolini D, Bighin C, Levaggi A, Giraudi S, D'Alonzo A, Vaglica M, Blondeaux E, Sertoli MR, Pronzato P, Del Mastro L. Poggio F, et al. Among authors: lambertini m. Breast. 2017 Jun;33:104-108. doi: 10.1016/j.breast.2017.03.011. Epub 2017 Mar 27. Breast. 2017. PMID: 28360014 Review.
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L. Lambertini M, et al. Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11. Clin Breast Cancer. 2017. PMID: 28479052
Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M. Solinas C, et al. Among authors: lambertini m. Cancer Treat Rev. 2017 Jun;57:8-15. doi: 10.1016/j.ctrv.2017.04.005. Epub 2017 May 2. Cancer Treat Rev. 2017. PMID: 28525810 Review.
Breast cancer treatment-induced cardiotoxicity.
Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Martel S, et al. Among authors: lambertini m. Expert Opin Drug Saf. 2017 Sep;16(9):1021-1038. doi: 10.1080/14740338.2017.1351541. Epub 2017 Jul 18. Expert Opin Drug Saf. 2017. PMID: 28697311 Review.
436 results